(CS-055) Reviving Stalled Wounds: A Case Series on the Clinical Impact of a Borate-Based Bioactive Glass Fiber Matrix in Complex Patients

Introduction: Chronic and complex wounds present significant clinical challenges, particularly in medically fragile populations.
Advanced wound care products are increasingly being used to stimulate healing in wounds that are refractory to standard
interventions. A critical step in this process is wound bed preparation—removing nonviable tissue, managing exudate, and
optimizing the local wound environment to facilitate granulation and epithelialization.1-3 This case series evaluates the use
of a Borate-Based Bioactive Glass Fiber Matrix (BBGFM) in three diverse patients with non-healing wounds, highlighting the
skin substitute’s role in potentially facilitating proper wound bed preparation, formation and eventual wound closure

Methods: Three patients with complex wounds were treated with BBGFM following periods of stalled healing. Clinical
context, wound characteristics, and comorbidities were recorded. Wound progression was monitored through serial
measurements and photographic documentation. The BBGFM was applied per manufacturer guidelines until closure or
evidence of meaningful progression was observed

Results: Case 1 involved a 93-year-old with a traumatic lower extremity laceration from a cardboard box. Treatment with
the BBGFM began on 03/14/2025, and complete wound closure was achieved by, 05/02/2025 with 5 applications
representing a healing time of 7 weeks.
Case 2 featured a 64-year-old with a right foot abscess complicated by alcohol-related systemic illness including portal
hypertension, acute renal failure, and ascites. After multiple procedural interventions during a prolonged hospitalization
and systemic support, the BBGFM was initiated on 07/19/2024, with complete closure achieved by 9/20/2024 with 6
applications in 9 weeks.
Case 3 was a 52-year-old with a non-healing post-arthroplasty wound following a motor vehicle collision (MVC). After
months of minimal improvement, the BBGFM was initiated on 11/1/2024. By 12/13/2024, a 47.74% percent area
reduction (PAR) was documented, with wound bed granulation and epithelialization signaling readiness for subsequent
wound closure intervention (6-week period)

Discussion: This case series demonstrates the utility of the BBGFM in facilitating wound healing across diverse etiologies and patient
populations. Notably, two cases achieved complete wound closure within 9 and 16 weeks, respectively, while the third showed
marked improvement after prolonged stagnation. These results suggest that the BBGFM may potentially provide critical
support in reinitiating wound healing, even in medically complex or previously non-responsive wounds.